Overview

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety and tolerability of TAK-063 when administered as multiple oral doses at escalating dose levels in participants with stable schizophrenia and in healthy Japanese participants.
Phase:
Phase 1
Details
Lead Sponsor:
Takeda